| Today's Top Story |  |  | | - MannKind licenses potential cancer drugs to Colby Pharmaceutical
MannKind granted Colby Pharmaceutical exclusive global rights to develop and market disease-specific antigen compounds and intra-lymph node delivery technologies from its MKC1106 active immunotherapy programs. Colby will use the licensed compounds and technologies to develop treatments for multiple cancer types. The deal entitles MannKind to about $140 million in upfront and milestone fees as well as royalties. Genetic Engineering & Biotechnology News (11/13)       | Health Care & Policy | | | | - Lilly-Incyte's RA drug baricitinib shows promise in trial
A Phase II trial found that Eli Lilly and Co. and Incyte's experimental drug baricitinib sustained its effectiveness in relieving pain through 24 weeks of treatment among patients with mild to moderate rheumatoid arthritis who had an inadequate response to methotrexate. The partners plan to conduct four late-stage studies of baricitinib in patients who have not previously received methotrexate or injectable biotech drugs or biologics. Reuters (11/13) - Research links gene mutation with racial differences in some cancers
Scientists at Georgia Health Sciences University identified a mutation in the p53 tumor suppressor gene that might underlie racial differences in breast and colon cancers. Black people with a specific genetic profile are more likely than whites and Asians with a different genetic profile to get breast or colorectal cancers at a young age, the researchers say. The researchers compared patients' normal genome from blood with tissue samples from tumors to identify the mutation. The Augusta Chronicle (Ga.) (11/9) | Company & Financial News | | | | - Idera raises $7M to fund development
Idera Pharmaceuticals secured $7 million in a private placement of securities with Pillar Pharmaceuticals. The money will allow the Cambridge, Mass.-based firm to complete an ongoing midstage trial of its psoriasis drug candidate, IMO-3100. An announcement of the clinical development of IMO-8400 for lupus could come this month. Mass High Tech (Boston) (11/12)  | First class, non-stop, global connections.
BIO conferences provide strategic access for the biotech community to accelerate business relationships. We catalyze partnerships through our global portfolio of events, including the world's largest biotech gathering, the BIO International Convention. Learn more about BIO events. | | Food & Agriculture | | | | - U.K. group supports adoption of agricultural biotechnology
Jim Moseley, president of the Food and Drink Federation, called on the U.K. to allow the use of biotechnology in agriculture. Farmers are dealing with fewer resources and greater damage from disease, and they should be able to use biotechnology to boost food production, Moseley said during a conference in London. Farmers Guardian (U.K.) (11/13) | Industrial & Environmental | | | | - KiOR, INEOS Bio near commercial production of advanced biofuel
KiOR and INEOS Bio are getting closer to producing commercial quantities of cellulosic biofuels at their plants in Columbus, Miss., and Vero Beach, Fla., respectively. KiOR's plant will use wood and wood waste to produce "renewable crude" and has lined up buyers, including FedEx and a Chevron-Weyerhauser joint venture. INEOS is in the final stages of construction of a facility that would convert wood and waste into cellulosic ethanol. The New York Times (tiered subscription model) (11/13)  | |  | | The Buzz(CORPORATE ANNOUNCEMENTS)
| |  | |  |
| News from BIO | | | | - BIOtechNOW
BIOtechNOW is the first in a number of new products from BIO intended to enhance our communications with the biotech community -- not only with our members, but with other stakeholders as well. This e-newsletter, combined with its website, serves as our flagship in that effort. BIOtechNOW will offer original content that emphasizes the business needs of the industry; highlight BIO's advocacy efforts; and provide a portal to all BIO activities and events. Most importantly, it will spotlight for those outside the industry the value of biotechnology. Sign up for the e-newsletter.
| SmartQuote | | | |  | The best way to find out if you can trust somebody is to trust them."
--Ernest Hemingway,
American author and journalist  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Tuesday, November 13, 2012
- Monday, November 12, 2012
- Friday, November 09, 2012
- Thursday, November 08, 2012
- Wednesday, November 07, 2012
| | | Lead Editor: Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | | | | | © 1999-2012 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment